BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» FDA issues guidance for development of non-addictive alternatives to opioids
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA issues guidance for development of non-addictive alternatives to opioids
Feb. 10, 2022
No Comments
Aiming to spur development of non-addictive pain therapies, as part of ongoing efforts to tackle the opioid crisis, the U.S. FDA released draft guidance Feb. 10 that outlines recommendations regarding development of opioid alternatives.
BioWorld
Regulatory
U.S.
FDA